GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
116 articles in GLP-1 & Metabolic · page 5 of 10
GLP-1s in Pregnancy and Before Conception
GLP-1 drugs are not recommended in pregnancy, and labels call for stopping weeks to months before conceiving. What's known, and what isn't.
Read →"Ozempic Face": Facial Aging and Rapid Fat Loss
Ozempic face is what happens to facial volume during any rapid weight loss, not a pharmacological side effect. The mechanism, and the options.
Read →Ozempic vs Mounjaro: Which and For Whom
Semaglutide and tirzepatide both drive weight loss, but they hit different receptors and rest on different evidence. How to think about the choice.
Read →Retatrutide vs Tirzepatide: Triple vs Dual Agonist
Tirzepatide hits two receptors and is approved. Retatrutide adds a third and posted bigger early numbers — but it is still investigational.
Read →Stopping a GLP-1 Before Surgery: The Anesthesia Guidance
GLP-1 drugs slow stomach emptying, and that can matter under anesthesia even after a normal fast. Here's what anesthesiologists are actually recommending.
Read →What Is Ozempic? A Plain-Language Explainer
Ozempic is a weekly injectable diabetes medicine that became a household name. What it is, how it works, and how it differs from Wegovy.
Read →What Is Zepbound? A Plain-Language Explainer
Zepbound is Eli Lilly's weekly injectable for chronic weight management. What tirzepatide is, what the trials showed, and how it differs from Mounjaro.
Read →Does Ozempic Cause Hair Loss? What the Evidence Shows
Hair shedding on GLP-1s is real but usually indirect — a response to rapid weight loss rather than the drug itself. What the trials report and what helps.
Read →Mounjaro vs Zepbound: Same Drug, Different Label
Mounjaro and Zepbound are both tirzepatide from Eli Lilly. The difference is the approved indication, not the molecule inside the pen.
Read →Ozempic vs Wegovy: Same Drug, Different Label
Ozempic and Wegovy are both semaglutide made by the same company. What actually separates them is dose, approved use, and how they're paid for.
Read →Reading a GLP-1 Headline Without Getting Misled
Relative versus absolute risk, surrogate versus hard endpoints, and who got counted — reading GLP-1 headlines against the real trial numbers.
Read →GLP-1s and Bone Density: An Open Question
Rapid weight loss can affect bone. What the limited trial data shows on GLP-1s and bone density, and why it is worth watching.
Read →